Baris Erdogan, currently Vice President, Site & Patient Networks, at Clinerion, has been promoted by the Board of Directors to the position of Chief Executive Officer as of January 1st, 2021. After a three-year tenure, Clinerion’s current CEO, Ian Rentsch,has decided to step down for personal reasons and to return to his family in Berlin by the end of January, 2021
Ian Rentsch joined Clinerion as Chief Executive Officer from IQVIA in April, 2018, with over 24 years’ experience in corporate affairs, outsourcing management and clinical research development positions at leading multinational companies, including biopharma in emerging markets. Rentschsuccessfully executed Clinerion’s strategy, with the goal to become the leader in real-world data solutions outside the U.S.A. In the three years of his tenure, Clinerion doubled its revenues year-on-year, as well as doubled the global footprint and reach from our hospital network. Rentschestablished Clinerion as a strong and efficient partner for pharma, CROs and hospitals.
Baris Erdogan, PhD, has been named the new CEO of Clinerion and will take over from Ian Rentsch on January 1st, 2021. Erdogan, currently Vice President, Site & Patient Networks, started his career as a computer engineer from the Middle East Technical University and holds an M.Sc. and a Ph.D. in educational technology. His expertise and experience include management of innovative medical informatics projects and the implementation of end-to-end healthcare IT enterprise information systems, both in the public and private sectors. Erdoganjoined Clinerion in 2013 and has been the main driver of the continued rapid expansion of Clinerion’s global clinical network, currently with real-time, live data reach of more than 33 million patients in 17 countries in Europe, Asia and Latin America.
Pierre Jaccoud, Chairman of Clinerion’sBoard of Directors, says: “We thank Ian for his outstanding achievements in developing Clinerion as a leader in the fast-developing world of real-world data solutions. We regret losing Ian, but sympathize with his personal reasons for returning to Berlin to focus on his personal health and family. We wish Ian every success and are thankful that we can continue our relationship beyond his formal exit date. Ian will support the transition to Baris Erdoganuntil the end of January, 2021. For the Board of Directors, Barisis the ideal successor as CEO. He knows Clinerion, our excellent employees and outstanding technology, and has in-depth understanding of clinical research. He will continue to drive Clinerion on the path set by Ian. We are happy that we can fill the CEO position through internal promotion, which demonstrates the quality of “the Bench” at Clinerion. He has the full support of the Board.
About Clinerion
Clinerion accelerates clinical research and medical access to treatments for patients. We generate real-world data from our global network of partner hospitals for Real World Evidence analyses. Clinerion’s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments.Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. Researchers gain access to real-time, longitudinal patient data from electronic health records for analysis. We enable pharmaceutical companies, CROs and SMOs to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s Patient Network Explorer also provides a platform for integration of diverse patient data sources into real-world data ecosystems. Clinerion’s proprietary technologies comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.
